Posted inCardiology Clinical Updates news
Olfactory Receptor Signaling as a Novel Antiplatelet Strategy: OR2L13 Activation, HSP27 Phosphorylation, and Cytoskeletal Control of Arterial Thrombosis
A 2026 Circulation study identifies OR2L13 agonism as a first-in-class platelet inhibitory strategy that suppresses aggregation and arterial thrombosis through HSP27-dependent actin remodeling without an apparent hemostatic penalty in preclinical models.